---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-004265"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:57:09.804048+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dermata's XYNGARI Phase 3 trial shows stat sig benefit at 4 weeks in moderate-to-severe acne

## Summary
- IGA treatment success: 11.9% XYNGARI vs 6.2% placebo (p<0.05) at week 4, after 4 weekly doses.
- Inflammatory lesion count mean change: -11.4 XYNGARI vs -8.6 placebo (p<0.001).
- Non-inflammatory lesion count mean change: -12.4 XYNGARI vs -8.8 placebo (p<0.001).
- Data support earlier positive week 12 topline results for all primary endpoints.

## SEC filing metadata
- accession: 0001654954-25-004265
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495425004265/0001654954-25-004265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495425004265/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-004265
- JSON: https://secwatch.observer/filing/0001654954-25-004265.json
- Plain text: https://secwatch.observer/filing/0001654954-25-004265.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.